Schizophrenia is a chronic neuropsychiatric brain disorder that has devastating personal impact and rising healthcare costs. Dysregulation of glutamatergic neurotransmission has been implicated in the pathobiology of the disease, attributed largely to the hypofunction of the N-methyl-d-aspartate (NMDA) receptor. Currently, there is a major gap in mechanistic analysis as to how endogenous modulators of the NMDA receptors contribute to the onset and progression of the disease. We present a systematic review of the neurobiology and the role of endogenous NMDA receptor antagonists in animal models of schizophrenia, and in patients. We discuss their neurochemical origin, release from neurons and glia with action mechanisms, and functional effects, which might contribute toward the impairment of neuronal processes underlying this complex pathological state. We consider clinical evidence suggesting dysregulations of endogenous NMDA receptor in schizophrenia, and highlight the pressing need in future studies and emerging directions, to restore the NMDA receptor functions for therapeutic benefits.

Department of Experimental Neurobiology National Institute of Mental Health Klecany Czech Republic

Department of Psychiatry and Medical Psychology 3rd Faculty of Medicine Charles University Prague 10 Czech Republic

Zobrazit více v PubMed

Bleuler E, Jung C. Komplexe und Krankheitsursachen bei Dementia praecox. Zentralblatt für Nervenheilkunde und Psychiatrie. 1908;31:220-227.

Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh: ES Livington; 1919. Translated by RM Barclay.

Gaebel W, Zielasek J. Schizophrenia in 2020: trends in diagnosis and therapy. Psychiatry Clin Neurosci. 2015;69:661-673.

Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388:86-97.

Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.

Harvey PD, Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry. 2012;11:73-79.

Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006;2:531-536.

Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519-534.

Tripathi A, Kar SK, Shukla R. Cognitive Deficits in schizophrenia: understanding the biological correlates and remediation strategies. Clin Psychopharm Neu. 2018;16:7-17.

Lesh TA, Niendam TA, Minzenberg MJ, Carter CS. Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology. 2011;36:316-338.

Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience. 2013;251:90-107.

Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiat Clin Neuros. 2019;73:204-215.

McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15-33.

Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29:97-115.

Snyder MA, Gao WJ. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci. 2013;7.

Nakazawa K, Jeevakumar V, Nakao K. Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. NPJ Schizophr. 2017;3:7.

Javitt DC. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci. 2010;47:4-16.

Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl). 2005;179:4-29.

Madden DR. The structure and function of glutamate receptor ion channels. Nat Rev Neurosci. 2002;3:91-101.

Ulbrich MH, Isacoff EY. Rules of engagement for NMDA receptor subunits. P Natl Acad Sci USA. 2008;105:14163-14168.

Paoletti P. Molecular basis of NMDA receptor functional diversity. Eur J Neurosci. 2011;33:1351-1365.

Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383-400.

Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 1994;12:529-540.

Vyklicky V, Korinek M, Smejkalova T, et al. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res. 2014;63:S191-S203.

McBain CJ, Mayer ML. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev. 1994;74:723-760.

Clements JD, Westbrook GL. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron. 1991;7:605-613.

Pachernegg S, Strutz-Seebohm N, Hollmann M. GluN3 subunit-containing NMDA receptors: not just one-trick ponies. Trends Neurosci. 2012;35:240-249.

Chen PE, Geballe MT, Katz E, et al. Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol. 2008;586:227-245.

Erreger K, Geballe MT, Kristensen A, et al. Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol. 2007;72:907-920.

Sainio EL, Pulkki K, Young SN. L-Tryptophan: biochemical, nutritional and pharmacological aspects. Amino Acids. 1996;10:21-47.

Plitman E, Iwata Y, Caravaggio F, et al. Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2017;43:764-777.

Hoglund E, Overli O, Winberg S. Tryptophan metabolic pathways and brain serotonergic activity: a comparative review. Front Endocrinol (Lausanne). 2019;10:158.

Han Q, Cai T, Tagle DA, Li J. Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci. 2010;67:353-368.

Heredi J, Berko AM, Jankovics F, et al. Astrocytic and neuronal localization of kynurenine aminotransferase-2 in the adult mouse brain. Brain Struct Funct. 2017;222:1663-1672.

Dang Y, Dale WE, Brown OR. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic Biol Med. 2000;28:615-624.

Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56:2007-2017.

Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem. 1989;52:1319-1328.

Birch PJ, Grossman CJ, Hayes AG. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol. 1988;154:85-87.

Prescott C, Weeks AM, Staley KJ, Partin KM. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett. 2006;402:108-112.

Stone TW. Does kynurenic acid act on nicotinic receptors? An assessment of the evidence. J Neurochem. 2020;152:627-649.

Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21:7463-7473.

Carpenedo R, Pittaluga A, Cozzi A, et al. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci. 2001;13:2141-2147.

Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophrenia Bull. 2018;44:75-83.

Kindler J, Lim CK, Weickert CS, et al. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol Psychiatry. 2020;25(11):2860-2872.

Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;1073-1074:25-37.

Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis. 2004;15:618-629.

Lestage J, Verrier D, Palin K, Dantzer R. The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun. 2002;16:596-601.

Javitt DC. Distress intolerance, kynurenic acid, and schizophrenia. JAMA Psychiatry. 2014;71:749-750.

Jayawickrama GS, Nematollahi A, Sun G, Gorrell MD, Church WB. Inhibition of human kynurenine aminotransferase isozymes by estrogen and its derivatives. Sci Rep. 2017;7:17559.

Meltzer-Brody S, Howard LM, Bergink V, et al. Postpartum psychiatric disorders. Nat Rev Dis Primers. 2018;4:18022.

Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004;56:255-260.

Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 2007;33:797-804.

Chess AC, Landers AM, Bucci DJ. L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res. 2009;201:325-331.

Shepard PD, Joy B, Clerkin L, Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology. 2003;28:1454-1462.

Pocivavsek A, Thomas MA, Elmer GI, Bruno JP, Schwarcz R. Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology (Berl). 2014;231:2799-2809.

Pershing ML, Bortz DM, Pocivavsek A, et al. Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia. Neuropharmacology. 2015;90:33-41.

Pershing ML, Phenis D, Valentini V, et al. Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding. Psychopharmacology (Berl). 2016;233:3725-3735.

Potter MC, Elmer GI, Bergeron R, et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 2010;35:1734-1742.

Linderholm KR, Andersson A, Olsson S, et al. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology. 2007;53:918-924.

Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25:131-147.

Cai H, Cao T, Zhou X, Yao JK. Neurosteroids in schizophrenia: pathogenic and therapeutic implications. Front Psychiatry. 2018;9:73.

Ratner MH, Kumaresan V, Farb DH. Neurosteroid actions in memory and neurologic/neuropsychiatric disorders. Front Endocrinol (Lausanne). 2019;10:169.

Baulieu EE, Robel P. Neurosteroids: a new brain function?. J Steroid Biochem Mol Biol. 1990;37:395-403.

Baulieu EE, Robel P, Schumacher M. Neurosteroids: beginning of the story. Int Rev Neurobiol. 2001;46:1-32.

Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 1999;22:410-416.

Harteneck C. Pregnenolone sulfate: from steroid metabolite to TRP channel ligand. Molecules. 2013;18:12012-12028.

Schumacher M, Liere P, Akwa Y, et al. Pregnenolone sulfate in the brain: a controversial neurosteroid. Neurochem Int. 2008;52:522-540.

Weaver CE, Land MB, Purdy RH, Richards KG, Gibbs TT, Farb DH. Geometry and charge determine pharmacological effects of steroids on N-methyl-D-aspartate receptor-induced Ca2+ accumulation and cell death. J Pharmacol Exp Ther. 2000;293:747-754.

Vyklicky V, Krausova B, Cerny J, et al. Block of NMDA receptor channels by endogenous neurosteroids: implications for the agonist induced conformational states of the channel vestibule. Sci Rep-Uk. 2015;5:10935.

Tuem KB, Atey TM. Neuroactive steroids: receptor interactions and responses. Front Neurol. 2017;8:442.

Malayev A, Gibbs TT, Farb DH. Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br J Pharmacol. 2002;135:901-909.

Horak M, Vlcek K, Petrovic M, Chodounska H. Molecular mechanism of pregnenolone sulfate action at NR1/NR2B receptors. J Neurosci. 2004;24:10318-10325.

Petrovic M, Sedlacek M, Horak M, Chodounska H. 20-oxo-5beta-pregnan-3alpha-yl sulfate is a use-dependent NMDA receptor inhibitor. J Neurosci. 2005;25:8439-8450.

Wong P, Sze Y, Chang CCR, Lee J, Zhang X. Pregnenolone sulfate normalizes schizophrenia-like behaviors in dopamine transporter knockout mice through the AKT/GSK3 beta pathway. Transl Psychiat. 2015;5:e528..

Plescia F, Sardo P, Rizzo V, et al. Pregnenolone sulphate enhances spatial orientation and object discrimination in adult male rats: evidence from a behavioural and electrophysiological study. Behav Brain Res. 2014;258:193-201.

Vallee M, Mayo W, Darnaudery M, et al. Neurosteroids: deficient cognitive performance in aged rats depends on low pregnenolone sulfate levels in the hippocampus. Proc Natl Acad Sci U S A. 1997;94:14865-14870.

Monnet FP, Maurice T. The sigma1 protein as a target for the non-genomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects. J Pharmacol Sci. 2006;100:93-118.

Sliwinski A, Monnet FP, Schumacher M, Morin-Surun MP. Pregnenolone sulfate enhances long-term potentiation in CA1 in rat hippocampus slices through the modulation of N-methyl-D-aspartate receptors. J Neurosci Res. 2004;78:691-701.

Wang CS, Marx CE, Morrow AL, Wilson WA, Moore SD. Neurosteroid modulation of GABAergic neurotransmission in the central amygdala: a role for NMDA receptors. Neurosci Lett. 2007;415:118-123.

Rabinowitz A, Cohen SJ, Finn DA. The neurosteroid allopregnanolone impairs object memory and contextual fear memory in male C57BL/6J mice. Horm Behav. 2014;66:238-246.

Tokunaga S, McDaniel JR, Morrow AL, Matthews DB. Effect of acute ethanol administration and acute allopregnanolone administration on spontaneous hippocampal pyramidal cell neural activity. Brain Res. 2003;967:273-280.

Shimizu H, Ishizuka Y, Yamazaki H, Shirao T. Allopregnanolone increases mature excitatory synapses along dendrites via protein kinase A signaling. Neuroscience. 2015;305:139-145.

Ritsner M, Maayan R, Gibel A, Weizman A. Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. Eur Neuropsychopharmacol. 2007;17:358-365.

Marx CE, Stevens RD, Shampine LJ, et al. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology. 2006;31:1249-1263.

Grube M, Hagen P, Jedlitschky G. Neurosteroid transport in the brain: role of ABC and SLC transporters. Front Pharmacol. 2018;9:354.

Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry Clin Neurosci. 2014;68:432-440.

Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology. 2009;34:1885-1903.

Cai H, Zhou X, Dougherty GG, et al. Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naive patients with schizophrenia. Psychoneuroendocrinology. 2018;90:43-51.

Guerra GP, Rubin MA, Mello CF. Modulation of learning and memory by natural polyamines. Pharmacol Res. 2016;112:99-118.

Skatchkov SN, Antonov SM, Glia EatonMJ, Polyamines Glial. Role in brain function in health and disease. Biochem Mosc Suppl S. 2016;10:73-98.

Coleman CS, Hu G, Pegg AE. Putrescine biosynthesis in mammalian tissues. Biochem J. 2004;379:849-855.

Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. 2009;61:880-894.

Liu P, Gupta N, Jing Y, Zhang H. Age-related changes in polyamines in memory-associated brain structures in rats. Neuroscience. 2008;155:789-796.

Laube G, Veh RW. Astrocytes, not neurons, show most prominent staining for spermidine/spermine-like immunoreactivity in adult rat brain. Glia. 1997;19:171-179.

Bernstein HG, Muller M. The cellular localization of the L-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. Prog Neurobiol. 1999;57:485-505.

Masuko T, Kusama-Eguchi K, Sakata K, et al. Polyamine transport, accumulation, and release in brain. J Neurochem. 2003;84:610-617.

Pegg AE. Functions of polyamines in mammals. J Biol Chem. 2016;291:14904-14912.

Miller-Fleming L, Olin-Sandoval V, Campbell K, Ralser M. Remaining mysteries of molecular biology: the role of polyamines in the cell. J Mol Biol. 2015;427:3389-3406.

Williams K. Interactions of polyamines with ion channels. Biochem J. 1997;325:289-297.

Araneda RC, Zukin RS, Bennett MV. Effects of polyamines on NMDA-induced currents in rat hippocampal neurons: a whole-cell and single-channel study. Neurosci Lett. 1993;152:107-112.

Williams K. Extracellular modulation of NMDA receptors. Biol Nmda Receptor. 2009:235-257.

Araneda RC, Lan JY, Zheng X, Zukin RS, Bennett MV. Spermine and arcaine block and permeate N-methyl-D-aspartate receptor channels. Biophys J. 1999;76:2899-2911.

Lerma J. Spermine regulates N-methyl-D-aspartate receptor desensitization. Neuron. 1992;8:343-352.

McGurk JF, Bennett MV, Zukin RS. Polyamines potentiate responses of N-methyl-D-aspartate receptors expressed in xenopus oocytes. Proc Natl Acad Sci U S A. 1990;87:9971-9974.

Williams K. Mechanisms influencing stimulatory effects of spermine at recombinant N-methyl-D-aspartate receptors. Mol Pharmacol. 1994;46:161-168.

Richardson-Andrews RC. A central role for the polyamines in the aetiology of schizophrenia. Med Hypotheses. 1983;11:157-166.

Fiori LM, Turecki G. Implication of the polyamine system in mental disorders. J Psychiatry Neurosci. 2008;33:102-110.

Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci. 2002;22:2718-2729.

Baytunca MB, Ongur D. Plasma spermine levels in patients with schizophrenia and bipolar disorder: a preliminary study. Schizophr Res. 2020;216:534-535.

Flayeh KA. Spermidine oxidase activity in serum of normal and schizophrenic subjects. Clin Chem. 1988;34:401-403.

Das I, Adams C, Essali MA, Debelleroche J, Hirsch SR. Blood polyamines in schizophrenia: a study of clozapine in drug-resistant schizophrenic-patients. Schizophr Res. 1992;6:175.

Das I, Ramchand CN, Gliddon A, Hirsch SR. Nitric oxide, free radicals and polyamines may have a role in the membrane pathology of schizophrenia. Neuropsychobiology. 1998;37:65-67.

Gilad GM, Gilad VH, Casanova MF. Polyamines and their metabolizing enzymes in human frontal cortex and hippocampus: preliminary measurements in affective disorders. Biol Psychiatry. 1995;38:227-234.

Conway EL. Brain lesions and delayed water maze learning deficits after intracerebroventricular spermine. Brain Res. 1998;800:10-20.

Fruhauf PK, Ineu RP, Tomazi L, Duarte T, Mello CF, Rubin MA. Spermine reverses lipopolysaccharide-induced memory deficit in mice. J Neuroinflammation. 2015;12:3.

Uzbay T, Kayir H, Goktalay G, Yildirim M. Agmatine disrupts prepulse inhibition of acoustic startle reflex in rats. J Psychopharmacol. 2010;24:923-929.

Mikolajczak P, Okulicz-Kozaryn I, Kaminska E, Niedopad L, Polanska A, Gebka J. Effects of acamprosate and some polyamine site ligands of NMDA receptor on short-term memory in rats. Eur J Pharmacol. 2002;444:83-96.

Liu P, Jing Y, Collie ND, Dean B, Bilkey DK, Zhang H. Altered brain arginine metabolism in schizophrenia. Transl Psychiat. 2016;6:e871.

Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62:405-496.

Prakash A, Bharti K, Majeed AB. Zinc: indications in brain disorders. Fundam Clin Pharmacol. 2015;29:131-149.

Plum LM, Rink L, Haase H. The essential toxin: impact of zinc on human health. Int J Environ Res Public Health. 2010;7:1342-1365.

Petrilli MA, Kranz TM, Kleinhaus K, et al. The emerging role for zinc in depression and psychosis. Front Pharmacol. 2017;8:414.

Frederickson CJ. Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol. 1989;31:145-238.

Wenzel HJ, Cole TB, Born DE, Schwartzkroin PA, Palmiter RD. Ultrastructral localization of zinc transporter-3 (ZnT-3) to synaptic vesicle membranes within mossy fiber boutons in the hippocampus of mouse and monkey. Proc Natl Acad Sci U S A. 1997;94:12676-12681.

Martinez-Guijarro FJ, Soriano E, Del Rio JA, Lopez-Garcia C. Zinc-positive boutons in the cerebral cortex of lizards show glutamate immunoreactivity. J Neurocytol. 1991;20:834-843.

Salazar G, Craige B, Love R, Kalman D, Faundez V. Vglut1 and ZnT3 co-targeting mechanisms regulate vesicular zinc stores in PC12 cells. J Cell Sci. 2005;118:1911-1921.

Wang ZY, Li JY, Dahlstrom A, Danscher G. Zinc-enriched GABAergic terminals in mouse spinal cord. Brain Res. 2001;921:165-172.

Blakemore LJ, Trombley PQ. Zinc as a neuromodulator in the central nervous system with a focus on the olfactory bulb. Front Cell Neurosci. 2017;11:297.

Barberis A, Cherubini E, Mozrzymas JW. Zinc inhibits miniature GABAergic currents by allosteric modulation of GABA(A) receptor gating. J Neurosci. 2000;20:8618-8627.

Joe P, Petrilli M, Malaspina D, Weissman J. Zinc in schizophrenia: a meta-analysis. Gen Hosp Psychiatry. 2018;53:19-24.

Doboszewska U, Wlaz P, Nowak G, Radziwon-Zaleska M, Cui RJ, Mlyniec K. Zinc in the monoaminergic theory of depression: its relationship to neural plasticity. Neural Plast. 2017;2017:3682752.

Marger L, Schubert CR, Bertrand D. Zinc: an underappreciated modulatory factor of brain function. Biochem Pharmacol. 2014;91:426-435.

Chen N, Moshaver A, Raymond LA. Differential sensitivity of recombinant N-methyl-D-aspartate receptor subtypes to zinc inhibition. Mol Pharmacol. 1997;51:1015-1023.

Rachline J, Perin-Dureau F, Le Goff A, Neyton J, Paoletti P. The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J Neurosci. 2005;25:308-317.

Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P, Powers JL. Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci. 1998;18:6163-6175.

Scarr E, Udawela M, Greenough MA, et al. Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia. NPJ Schizophr. 2016;2:16002.

Mortazavi M, Farzin D, Zarhghami M, Hosseini SH, Mansoori P, Nateghi G. Efficacy of zinc sulfate as an add-on therapy to risperidone versus risperidone alone in patients with schizophrenia: a double-blind randomized placebo-controlled trial. Iran J Psychiatry Behav Sci. 2015;9:e853.

Cole TB, Martyanova A, Palmiter RD. Removing zinc from synaptic vesicles does not impair spatial learning, memory, or sensorimotor functions in the mouse. Brain Res. 2001;891:253-265.

Martel G, Hevi C, Kane-Goldsmith N, Shumyatsky GP. Zinc transporter ZnT3 is involved in memory dependent on the hippocampus and perirhinal cortex. Behav Brain Res. 2011;223:233-238.

Adlard PA, Parncutt JM, Finkelstein DI, Bush AI. Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease?. J Neurosci. 2010;30:1631-1636.

Izumi Y, Auberson YP, Zorumski CF. Zinc modulates bidirectional hippocampal plasticity by effects on NMDA receptors. J Neurosci. 2006;26:7181-7188.

Joshi M, Akhtar M, Najmi AK, Khuroo AH, Goswami D. Effect of zinc in animal models of anxiety, depression and psychosis. Hum Exp Toxicol. 2012;31:1237-1243.

Schoeler T, Petros N, Di Forti M, et al. Association between continued cannabis use and risk of relapse in first-episode psychosis: a quasi-experimental investigation within an observational study. Jama Psychiatry. 2016;73:1173-1179.

Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-Year follow-up after first hospitalization. Am J Psychiat. 2010;167:987-993.

Sanchez-Blazquez P, Rodriguez-Munoz M, Garzon J. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol. 2014;4:169.

Szutorisz H, Hurd YL. Epigenetic Effects of Cannabis Exposure. Biol Psychiat. 2016;79:586-594.

Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10:1665-1669.

De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003;2:5.

Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostag Oth Lipid M. 2009;89:112-119.

Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond). 2006;30 Suppl 1:S13-8.

Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005:299-325.

Gong JP, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006;1071:10-23.

Zou SL, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19:833.

Kruk-Slomka M, Dzik A, Budzynska B, Biala G. Endocannabinoid System: the Direct and Indirect Involvement in the Memory and Learning Processes-a Short Review. Mol Neurobiol. 2017;54:8332-8347.

Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76:70-81.

Sanchez-Blazquez P, Rodriguez-Munoz M, Vicente-Sanchez A, Garzon J. Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate. Antioxid Redox Signal. 2013;19:1766-1782.

Colizzi M, Weltens N, McGuire P, et al. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. Mol Psychiatry. 2019. https://doi.org/10.1038/s41380-019-0374-8.

Fan N, Yang H, Zhang J, Chen C. Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Delta9-THC exposure-impaired hippocampal synaptic plasticity. J Neurochem. 2010;112:691-702.

Brown TM, Brotchie JM, Fitzjohn SM. Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. J Neurosci. 2003;23:11073-11077.

Antonelli T, Tomasini MC, Tattoli M, et al. Prenatal exposure to the CB1 receptor agonist WIN 55,212-2 causes learning disruption associated with impaired cortical NMDA receptor function and emotional reactivity changes in rat offspring. Cereb Cortex. 2005;15:2013-2020.

Hampson RE, Miller F, Palchik G, Deadwyler SA. Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity. Neuropharmacology. 2011;60:944-952.

Vicente-Sanchez A, Sanchez-Blazquez P, Rodriguez-Munoz M, Garzon J. HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity. Mol Brain. 2013;6:42.

Navarrete M, Araque A. Endocannabinoids mediate neuron-astrocyte communication. Neuron. 2008;57:883-893.

Ruggiero RN, Rossignoli MT, De Ross JB, Hallak JEC, Leite JP, Bueno-Junior LS. Cannabinoids and Vanilloids in Schizophrenia: neurophysiological Evidence and Directions for Basic Research. Front Pharmacol. 2017;8:399.

Rodriguez-Munoz M, Sanchez-Blazquez P, Callado LF, Meana JJ, Garzon-Nino J. Schizophrenia and depression, two poles of endocannabinoid system deregulation. Transl Psychiatry. 2017;7:1291.

Schneider M, Koch M. The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats. Behav Pharmacol. 2002;13:29-37.

Bortolato M, Campolongo P, Mangieri RA, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 2006;31:2652-2659.

Pedrazzi JFC, Issy AC, Gomes FV, Guimaraes FS, EA Del-Bel. Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology. 2015;232:3057-3065.

Long LE, Malone DT, Taylor DA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology. 2006;31:795-803.

Levin R, Peres FF, Almeida V, Calzavara MB, Zuardi AW, Hallak JEC, et al. Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain. Frontiers in Pharmacology. 2014:5.

Gururajan A, Taylor DA, Malone DT. Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia. Behav Brain Res. 2011;222:299-308.

Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63-74.

Venkatesan A, Adatia K. Anti-NMDA-Receptor Encephalitis: from Bench to Clinic. ACS Chem Neurosci. 2017;8:2586-2595.

Sharma R, Al-Saleem FH, Panzer J, et al. Monoclonal antibodies from a patient with anti-NMDA receptor encephalitis. Ann Clin Transl Neurol. 2018;5:935-951.

Jones BE, Tovar KR, Goehring A, et al. Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors. Sci Transl Med. 2019:11.

Dalmau J, Armangue T, Planaguma J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18:1045-1057.

Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013;70:1133-1139.

Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30:5866-5875.

Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;76:108-119.

Mikasova L, De Rossi P, Bouchet D, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;135:1606-1621.

Ladepeche L, Planaguma J, Thakur S, et al. NMDA Receptor Autoantibodies in Autoimmune Encephalitis Cause a Subunit-Specific Nanoscale Redistribution of NMDA Receptors. Cell Rep. 2018;23:3759-3768.

Gleichman AJ, Spruce LA, Dalmau J, Seeholzer SH, Lynch DR. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci. 2012;32:11082-11094.

Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis. 2010;5:31.

Planaguma J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138:94-109.

Li Y, Tanaka K, Wang L, Ishigaki Y, Kato N. Induction of Memory Deficit in Mice with Chronic Exposure to Cerebrospinal Fluid from Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Tohoku J Exp Med. 2015;237:329-338.

Kersten M, Rabbe T, Blome R, et al. Novel Object Recognition in Rats With NMDAR Dysfunction in CA1 After Stereotactic Injection of Anti-NMDAR Encephalitis Cerebrospinal Fluid. Front Neurol. 2019;10:586.

Masopust J, Andrys C, Bazant J, Vysata O, Kuca K, Valis M. Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia. Neuropsychiatr Dis Treat. 2015;11:619-623.

Rhoads J, Guirgis H, McKnight C, Duchemin AM. Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia. Schizophr Res. 2011;129:213-214.

Zandi MS, Irani SR, Lang B, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol. 2011;258:686-688.

Tsutsui K, Kanbayashi T, Tanaka K, et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry. 2012;12:37.

Castillo-Gomez E, Oliveira B, Tapken D, et al. All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class. Mol Psychiatry. 2017;22:1776-1784.

Yamamura S, Hoshikawa M, Dai K, et al. ONO-2506 inhibits spikewave discharges in a genetic animal model without affecting traditional convulsive tests via gliotransmission regulation. Brit J Pharmacol. 2013;168:1088-1100.

Mony L, Zhu S, Carvalho S, Paoletti P. Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines. EMBO J. 2011;30:3134-3146.

Moriyama Y, Hatano R, Moriyama S, Uehara S. Vesicular polyamine transporter as a novel player in amine-mediated chemical transmission. Biochim Biophys Acta, Biomembr. 2020:183208.

Sensi SL, Paoletti P, Bush AI, Sekler I. Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci. 2009;10:780-U38.

Xu YS, Xiao GR, Liu L, Lang ML. Zinc transporters in Alzheimer's disease. Mol Brain. 2019;12:106.

Endogenous Modulators of NMDA Receptor Control Dendritic Field Expansion of Cortical Neurons

Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases